Morgan Stanley’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $295 | Sell |
168
-281
| -63% | -$493 | ﹤0.01% | 7521 |
|
|
2025
Q1 | $610 | Sell |
449
-150
| -25% | -$204 | ﹤0.01% | 7346 |
|
|
2024
Q4 | $2.27K | Sell |
599
-100
| -14% | -$379 | ﹤0.01% | 7176 |
|
|
2024
Q3 | $1.89K | Hold |
699
| – | – | ﹤0.01% | 7142 |
|
|
2024
Q2 | $2.17K | Sell |
699
-500
| -42% | -$1.55K | ﹤0.01% | 7052 |
|
|
2024
Q1 | $5.44K | Sell |
1,199
-1,102
| -48% | -$5K | ﹤0.01% | 6874 |
|
|
2023
Q4 | $15.8K | Buy |
2,301
+760
| +49% | +$5.23K | ﹤0.01% | 6731 |
|
|
2023
Q3 | $9.71K | Sell |
1,541
-190
| -11% | -$1.2K | ﹤0.01% | 6739 |
|
|
2023
Q2 | $14.4K | Hold |
1,731
| – | – | ﹤0.01% | 6672 |
|
|
2023
Q1 | $7.61K | Buy |
1,731
+10
| +0.6% | +$44 | ﹤0.01% | 6961 |
|
|
2022
Q4 | $10.2K | Sell |
1,721
-786
| -31% | -$4.64K | ﹤0.01% | 6928 |
|
|
2022
Q3 | $18K | Buy |
2,507
+32
| +1% | +$230 | ﹤0.01% | 6841 |
|
|
2022
Q2 | $36K | Sell |
2,475
-21
| -0.8% | -$305 | ﹤0.01% | 6760 |
|
|
2022
Q1 | $95K | Sell |
2,496
-728
| -23% | -$27.7K | ﹤0.01% | 6344 |
|
|
2021
Q4 | $252K | Buy |
+3,224
| New | +$252K | ﹤0.01% | 5941 |
|
|
2021
Q2 | – | Sell |
-13
| Closed | -$1K | – | 7792 |
|
|
2021
Q1 | $1K | Buy |
+13
| New | +$1K | ﹤0.01% | 7372 |
|